Helen Hayes Hospital is conducting a medical research study for individuals who have experienced an ischemic stroke and continue to have problems with their ability to feel or move with either their lower or upper body. Individuals who are experiencing these chronic deficits after an ischemic stroke are being recruited for the study. The results of the research will help doctors learn more about the safety of Dalfampridine when treating patients who have experienced a stroke. The United States Food and Drug Administration (FDA) has already approved Dalfampridine for patients with multiple sclerosis (MS) to help improve their abilities to walk. Dalfampridine has not been studied in individuals recovering from stroke. The use of Dalfampridine in this study is investigational.
To pre-qualify for this study, an individual must meet the following criteria:
· Be between 18 and 85 years of age
· Have had a stroke six months ago or longer
· Have a history of problems with the ability to feel or move due to the stroke
· Must not have had a history of seizures, with the exception of simple febrile seizures
· Must not have any moderate or severe kidney impairments
· Must not have had Botox in the last two months.
All study-related visits, tests and study drugs will be provided at no cost. In addition, compensation for time and travel will be provided. To learn more about this study, contact: Laura Tenteromano, R.N. at 845-786-4854.